Cosentyx is a medication used to treat several autoimmune diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. The recommended dosage for Cosentyx varies depending on the condition being treated and the patient's weight.

According to the drug label approved by the US Food and Drug Administration (FDA) [2], the recommended starting dose for Cosentyx for the treatment of moderate to severe plaque psoriasis in adults is 300 mg by subcutaneous injection at weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks. For the treatment of psoriatic arthritis, the recommended starting dose is 150 mg or 300 mg by subcutaneous injection at weeks 0, 1, 2, 3, and 4, followed by 150 mg or 300 mg every 4 weeks, depending on the patient's weight. For the treatment of ankylosing spondylitis, the recommended starting dose is 150 mg by subcutaneous injection at weeks 0, 1, 2, 3, and 4, followed by 150 mg every 4 weeks.

In some cases, the dosage of Cosentyx may be increased or decreased depending on the patient's response to treatment. According to a study published in the Clinical and Experimental Dermatology journal [3], the dosage of Cosentyx can be increased to 300 mg every 2 weeks for patients with inadequate response to the standard dose of 300 mg every 4 weeks. The study also suggests that a dosage reduction to 150 mg every 4 weeks may be considered for patients who achieve sustained disease control.

In conclusion, the recommended Cosentyx dosage increments vary depending on the condition being treated and the patient's weight. The dosage may be increased or decreased based on the patient's response to treatment. It is important to follow the dosage instructions provided by a healthcare professional to ensure safe and effective treatment.

Sources:
[2] FDA. Cosentyx Label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125504s048lbl.pdf
[3] Clinical and Experimental Dermatology. Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis. https://academic.oup.com/ced/article-pdf/47/11/1968/48487296/ced1968.pdf